All In Biotech

Drug Trial Radar · NCT06827613

A Study of Invikafusp Alfa (STAR0602), a Selective T Cell Receptor (TCR)-Targeting, Bifunctional Antibody-fusion Molecule, in Combination With Sacituzumab Govitecan in Participants With Advanced Solid Tumors

A Phase 1b/2, Open-label Study to Investigate the Safety and Efficacy of Invikafusp Alfa (STAR0602), a Selective T Cell Receptor (TCR)-Targeting, Bifunctional Antibody-fusion Molecule, in Combination With Sacituzumab Govitecan in Participants With Unresectable, Locally Advanced, or Metastatic Solid Tumors (START-002)

Last checked: Nov 19, 2026Latest source record: Sep 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

50

Planned (sponsor's estimate)

Start

Mar 24, 2025

Primary completion

Jan 2027

Study completion Jan 2028

Sponsor

Lead sponsor
Marengo Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Feb 14, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 1b/2, Open-label Study to Investigate the Safety and Efficacy of Invikafusp alfa (STAR0602), a Selective T Cell Receptor (TCR)-targeting, Bifunctional Antibody-fusion Molecule, in Combination with Sacituzumab Govitecan in Participants with Unresectable, Locally Advanced, or Metastatic Solid Tumors.

Conditions

  • Triple Negative Locally Advanced Non-resectable Breast Cancer
  • HR+, HER2-, Advanced Breast Cancer

Interventions

  • STAR0602Drug

    solution, intravenous infusion

  • Sacituzumab Govitecan (SG)Drug

    intravenous infusion, 10mg/kg

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1 (Safety Run-In): Number of Participants with Dose Limiting Toxicites (DLTs)Time frame: 21 days following the first dose of STAR0602 + Sacituzumab Govitecan
  2. Phase 1 and 2 (Safety Run-In and Cohort Expansion): Number of Participants with Adverse Events and Serious Adverse EventsTime frame: Up to 3 years
  3. Phase 1 and 2 (Safety Run-In and Cohort Expansion): Percentage of participants with Overall Objective Tumor Responses (ORR)Time frame: Up to 3 years

Locations

8 sites in 2 countries. Site status is shown where the registry gives one.

  • USC Norris Comprehensive Cancer Center

    Los Angeles, California · Recruiting

  • UCLA Health

    Los Angeles, California · Recruiting

  • Massachusetts General Hospital Cancer Center

    Boston, Massachusetts · Recruiting

  • Ohio State University Comprehensive Cancer Center

    Columbus, Ohio · Recruiting

  • Sarah Cannon Research Institute

    Nashville, Tennessee · Recruiting

  • UT Health San Antonio MD Anderson Cancer Center

    San Antonio, Texas · Recruiting

  • BC Cancer

    Vancouver, British Columbia, Canada · Recruiting

  • Princess Margaret Cancer Centre

    Toronto, Ontario, Canada · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.